H. Lundbeck Q1 2026: 16% Revenue Surge, Strong EBITDA, & Vyepti Drives Growth
H. Lundbeck reports 2026 H1 revenue up 16 % and EBITDA over 1.9 bn DKK, driven by Vyepti®, with a bullish outlook and shareholder exchange offer.
2 minutes to read
H. Lundbeck A
Fast‑Track FDA Green‑Light for Lundbeck’s Narcolepsy Drug Lu AH69593
FDA grants Fast‑Track status to Lundbeck’s Lu AH69593, an oral orexin agonist for narcolepsy, speeding development and boosting patient hope and investor confidence.
2 minutes to read